S Salloway

Summary

Affiliation: Butler Hospital
Country: USA

Publications

  1. pmc Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease
    Pierre Tariot
    Banner Alzheimer s Institute, 901 E Willetta Street, Third Floor, Phoenix, AZ 85006, USA
    BMC Res Notes 5:283. 2012
  2. doi request reprint Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease
    Stephen Salloway
    Brown Alpert Medical School, Providence, RI 02906, USA
    Am J Alzheimers Dis Other Demen 27:421-32. 2012
  3. ncbi request reprint Clinical and pathological examples of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia
    Stephen Salloway
    Warren Alpert Medical School of Brown University, USA
    Med Health R I 95:207-9. 2012
  4. pmc Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease
    Randall J Bateman
    Department of Neurology, Washington University School of Medicine, 660 S, Euclid, Campus Box 8111, St Louis, MO 63110, USA
    Alzheimers Res Ther 3:1. 2011
  5. ncbi request reprint Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial
    S Salloway
    Department of Clinical Neurosciences, Brown University, Providence, RI, USA
    Neurology 63:651-7. 2004
  6. doi request reprint Disease-modifying therapies in Alzheimer's disease
    Stephen Salloway
    Department of Clinical Neuroscience, Division of Biology and Medicine, Brown Medical School, Providence, RI, USA
    Alzheimers Dement 4:65-79. 2008
  7. pmc A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
    S Salloway
    Butler Hospital, The Warren Alpert Medical School of Brown University, 345 Blackstone Blvd, Providence, RI 02906, USA
    Neurology 73:2061-70. 2009
  8. ncbi request reprint Improving the diagnosis and treatment of Alzheimer's disease
    Stephen Salloway
    Department of Neurology, Butler Hospital, Providence, RI 02906, USA
    Med Health R I 89:166-8. 2006
  9. ncbi request reprint Key lessons learned from short-term treatment trials of cholinesterase inhibitors for amnestic MCI
    Stephen Salloway
    Department of Clinical Neurosciences Brown Medical School, Rhode Island, USA
    Int Psychogeriatr 20:40-6. 2008
  10. pmc A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
    S Salloway
    Neurology and the Memory and Aging Program, Butler Hospital, 345 Blackstone Boulevard, Providence, RI 02906, USA
    Neurology 77:1253-62. 2011

Detail Information

Publications32

  1. pmc Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease
    Pierre Tariot
    Banner Alzheimer s Institute, 901 E Willetta Street, Third Floor, Phoenix, AZ 85006, USA
    BMC Res Notes 5:283. 2012
    ..The objective of this study was to assess the long-term safety and tolerability of donepezil 23 mg/day in patients with moderate to severe AD...
  2. doi request reprint Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease
    Stephen Salloway
    Brown Alpert Medical School, Providence, RI 02906, USA
    Am J Alzheimers Dis Other Demen 27:421-32. 2012
    ..In both subgroups, donepezil had acceptable tolerability; overall incidence of treatment-emergent adverse events was higher in patients receiving donepezil 23 mg/d compared with donepezil 10 mg/d...
  3. ncbi request reprint Clinical and pathological examples of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia
    Stephen Salloway
    Warren Alpert Medical School of Brown University, USA
    Med Health R I 95:207-9. 2012
    ..Disease-specific interventions, based on advances in genetic and molecular biomarkers, are likely to have the greatest impact when given in preclinical and early symptomatic phases...
  4. pmc Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease
    Randall J Bateman
    Department of Neurology, Washington University School of Medicine, 660 S, Euclid, Campus Box 8111, St Louis, MO 63110, USA
    Alzheimers Res Ther 3:1. 2011
    ..Clinical trials in autosomal-dominant Alzheimer's disease may test the amyloid hypothesis, determine the timing of treatment, and lead the way to Alzheimer's disease prevention...
  5. ncbi request reprint Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial
    S Salloway
    Department of Clinical Neurosciences, Brown University, Providence, RI, USA
    Neurology 63:651-7. 2004
    ..To evaluate the efficacy and safety of the acetylcholinesterase inhibitor donepezil in a placebo-controlled trial in patients with mild cognitive impairment (MCI)...
  6. doi request reprint Disease-modifying therapies in Alzheimer's disease
    Stephen Salloway
    Department of Clinical Neuroscience, Division of Biology and Medicine, Brown Medical School, Providence, RI, USA
    Alzheimers Dement 4:65-79. 2008
    ..Potentially neuroprotective and restorative treatments such as neurotrophins, neurotrophic factor enhancers, and stem cell-related approaches are also under investigation...
  7. pmc A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
    S Salloway
    Butler Hospital, The Warren Alpert Medical School of Brown University, 345 Blackstone Blvd, Providence, RI 02906, USA
    Neurology 73:2061-70. 2009
    ..Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD...
  8. ncbi request reprint Improving the diagnosis and treatment of Alzheimer's disease
    Stephen Salloway
    Department of Neurology, Butler Hospital, Providence, RI 02906, USA
    Med Health R I 89:166-8. 2006
  9. ncbi request reprint Key lessons learned from short-term treatment trials of cholinesterase inhibitors for amnestic MCI
    Stephen Salloway
    Department of Clinical Neurosciences Brown Medical School, Rhode Island, USA
    Int Psychogeriatr 20:40-6. 2008
    ..This paper reviews the key lessons learned from the first published short-term, placebo-controlled trial of a cholinesterase inhibitor for treatment of mild cognitive impairment (MCI)...
  10. pmc A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
    S Salloway
    Neurology and the Memory and Aging Program, Butler Hospital, 345 Blackstone Boulevard, Providence, RI 02906, USA
    Neurology 77:1253-62. 2011
    ..This randomized, double-blind, placebo-controlled, dose-ranging phase 2 study explored safety, efficacy, and biomarker effects of ELND005 (an oral amyloid anti-aggregation agent) in mild to moderate Alzheimer disease (AD)...
  11. doi request reprint Alzheimer disease: time to improve its diagnosis and treatment
    Stephen Salloway
    Department of Neurology, Butler Hospital, Providence, RI 02906, USA
    Cleve Clin J Med 76:49-58. 2009
    ..This review is aimed at primary care physicians, who are the first clinicians to see patients with Alzheimer disease and are responsible for their ongoing care throughout the course of their dementia...
  12. ncbi request reprint Galantamine treatment of vascular dementia: a randomized trial
    A P Auchus
    University of Tennessee Health Science Center, Department of Neurology, Memphis, TN 38163, USA
    Neurology 69:448-58. 2007
    ..To evaluate efficacy and safety of galantamine for patients with vascular dementia (VaD)...
  13. pmc Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, 46202, USA
    Clin Ther 32:1234-51. 2010
    ..We hypothesized that the loss of initial therapeutic benefit over time may be mitigated by higher doses of a cholinesterase inhibitor...
  14. ncbi request reprint Executive dysfunction and apathy predict functional impairment in Alzheimer disease
    Patricia A Boyle
    Brown Medical School, Providence, RI, USA
    Am J Geriatr Psychiatry 11:214-21. 2003
    ..The purpose of this study was to examine the extent to which executive cognitive dysfunction and frontally-mediated behavioral disturbances are associated with functional impairment in patients with mild-to-moderate Alzheimer disease (AD)...
  15. ncbi request reprint Assessing visuoconstructional performance in AD, MCI and normal elderly using the Beery Visual-Motor Integration Test
    Paul Malloy
    Department of Psychiatry and Human Behavior, Brown University, Providence, RI, USA
    Clin Neuropsychol 17:544-50. 2003
    ..Results revealed that the VMI is useful for discriminating AD from MCI. Qualitative errors produced on the VMI provide additional information beyond the standard score about the patient's cognitive status...
  16. ncbi request reprint The impact of behavioral symptoms on activities of daily living in patients with dementia
    L E Norton
    Butler Hospital, Brown University School of Medicine, Providence, RI, USA
    Am J Geriatr Psychiatry 9:41-8. 2001
    ..The authors conclude that behavioral measures add information over and above that available from cognitive tests in determining ADL functioning...
  17. pmc Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial
    Robert C Green
    Department of Neurology, Boston University School of Medicine, 72 E Concord St, L 320, Boston, MA 02118, USA
    JAMA 302:2557-64. 2009
    ..Tarenflurbil, a selective Abeta(42)-lowering agent, demonstrated encouraging results on cognitive and functional outcomes among mildly affected patients in an earlier phase 2 trial...
  18. ncbi request reprint Assessing motor and cognitive regulation in AD, MCI, and controls using the Behavioral Dyscontrol Scale
    Heather G Belanger
    Department of Psychiatry and Human Behavior, Brown University, Providence, RI, USA
    Arch Clin Neuropsychol 20:183-9. 2005
    ..Performance on the BDS was an independent predictor of ADLs in patient groups after controlling for the effects of performance on a memory measure...
  19. ncbi request reprint Effect of APOE genotype on microvascular basement membrane in Alzheimer's disease
    S Salloway
    Brown Medical School, Providence, RI, USA
    J Neurol Sci 203:183-7. 2002
    ..These data support the hypothesis that APOE4,4 is associated with thinning of the microvascular basement membrane in Alzheimer's disease...
  20. ncbi request reprint Dementia with Lewy bodies: a diagnostic and treatment challenge
    Stephen Salloway
    Brown Medical School, Butler Hospital, Providence, RI, USA
    Med Health R I 85:207-9. 2002
    ..There is much work to be done on the genetics and pathogenesis of DLB. More objectives diagnostic tests are needed, as are more controlled treatment trials for the specific symptoms of DLB...
  21. ncbi request reprint Impaired awareness, behavior disturbance, and caregiver burden in Alzheimer disease
    Susan Rymer
    Department of Neurology, Butler Hospital, Providence, Rhode Island 02906, USA
    Alzheimer Dis Assoc Disord 16:248-53. 2002
    ..We conclude that both patient awareness of memory deficit and behavioral disturbance impact caregiver burden, with behavioral disturbance making the greater contribution...
  22. pmc Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease
    David A Wolk
    Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 107:10256-61. 2010
    ....
  23. doi request reprint Cerebral cortical arteriolar angiopathy, vascular beta-amyloid, smooth muscle actin, Braak stage, and APOE genotype
    Edward G Stopa
    Department of Pathology, Brown University School of Medicine, Providence, RI 02903, USA
    Stroke 39:814-21. 2008
    ..We examined the associations among the vascular beta-amyloid levels, smooth muscle actin, wall thickness, and lumen diameter to achieve greater understanding of the arteriolar changes that accompany Alzheimer disease (AD)...
  24. ncbi request reprint Current and future treatments for Alzheimer's disease
    Stephen Salloway
    Memory and Aging Program, Butler Hospital, Providence, USA
    CNS Spectr 14:4-7; discussion 16-8. 2009
    ..This is a worldwide public health problem of the highest order, and there is a compelling need to develop new treatments and methods of earlier diagnosis need to slow the progression of the disease and lessen its impact...
  25. ncbi request reprint MRI subcortical hyperintensities in old and very old depressed outpatients: the important role of age in late-life depression
    Stephen Salloway
    Brown Medical School, Providence, RI, USA
    J Neurol Sci 203:227-33. 2002
    ..This study examined the severity of subcortical hyperintensities (SH) and the relationship between SH and depression characteristics in two samples of elderly depressed outpatients differing in age...
  26. ncbi request reprint The relationship of MRI subcortical hyperintensities to treatment response in a trial of sertraline in geriatric depressed outpatients
    Stephen Salloway
    Department of Neurology, Butler Hospital Providence, RI 02906, USA
    Am J Geriatr Psychiatry 10:107-11. 2002
    ..The association between SH and antidepressant treatment response in depressed geriatric outpatients remains unclear and deserves further investigation...
  27. ncbi request reprint Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial
    Sandra Black
    University of Toronto, Department of Medicine Division of Neurology, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Stroke 34:2323-30. 2003
    ..Clinical observations suggest that patients with vascular dementia (VaD) may benefit from treatment with cholinesterase inhibitors. This study evaluated the efficacy and safety of donepezil for relieving symptoms of dementia in VaD...
  28. ncbi request reprint Perspectives on depression, mild cognitive impairment, and cognitive decline
    David C Steffens
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA
    Arch Gen Psychiatry 63:130-8. 2006
    ....
  29. ncbi request reprint Taking the next steps in the treatment of Alzheimer's disease: disease-modifying agents
    Stephen Salloway
    CNS Spectr 13:11-4. 2008
  30. doi request reprint Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL
    Martin Dichgans
    Department of Neurology, Grosshadern Clinic, Ludwig Maximilian University, Munich, Germany
    Lancet Neurol 7:310-8. 2008
    ..We did a multicentre, 18-week, placebo-controlled, double-blind, randomised parallel-group trial to determine whether the cholinesterase inhibitor donepezil improves cognition in patients with CADASIL...
  31. ncbi request reprint Introduction: the prevalence of Alzheimer's disease--a growing crisis
    Stephen Salloway
    CNS Spectr 13:1. 2008
  32. ncbi request reprint Recommendations for best practices in the treatment of Alzheimer's disease in managed care
    Howard M Fillit
    Alzheimer s Drug Discovery Foundation and Institute for the Study of Aging New York, New York 10019, USA
    Am J Geriatr Pharmacother 4:S9-S24; quiz S25-S28. 2006
    ..However, these clinical guidelines have not been updated in the past few years...